Related Experiment Video

Updated: May 10, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Relationship between MIF-173 G/C polymorphism and susceptibility to chronic hepatitis B and HBV-induced liver

Ka Zhang1, Xingfei Pan, Xin Shu

  • 1Department of Infectious Diseases, The 3rd Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, People's Republic of China.

Cellular Immunology
|June 18, 2013
PubMed

Insights

Macrophage migration inhibitory factor (MIF) gene polymorphism, specifically MIF-173 C/C, is linked to a higher risk of chronic hepatitis B (CHB) and liver cirrhosis (HC) in Southern China. This finding suggests a potential genetic predisposition to these inflammatory liver diseases.

Area of Science:

  • Immunogenetics
  • Hepatology
  • Molecular Biology

Background:

  • Macrophage migration inhibitory factor (MIF) is a key pro-inflammatory cytokine involved in immune responses.
  • Functional polymorphisms in the MIF promoter region regulate its expression and are associated with various inflammatory diseases.
  • The specific association between MIF gene polymorphisms and chronic hepatitis B (CHB) or HBV-induced liver cirrhosis (HC) remained uninvestigated.

Purpose of the Study:

  • To investigate the association between MIF gene polymorphism at position -173 and the risk of developing CHB or HC.
  • To determine if MIF-173 genotypes correlate with clinical characteristics in patients with CHB or HC.

Main Methods:

  • Genotyping of the MIF-173 polymorphism was performed using samples from 95 CHB patients, 73 HC patients, and 90 healthy controls from Southern China.
  • Statistical analysis was employed to compare genotype and allele frequencies between patient groups and controls.

Main Results:

  • The frequency of the MIF-173 C/C genotype was significantly higher in both CHB and HC patient groups compared to healthy controls.
  • A statistically significant difference in the distribution of the MIF-173 C allele was observed between CHB patients and healthy controls.
  • No significant correlation was found between MIF-173 genotype and the clinical features of CHB or HC patients.

Conclusions:

  • The MIF-173 C/C polymorphism may be associated with an increased susceptibility to CHB and HC in the Southern Chinese population.
  • MIF gene polymorphism could serve as a potential genetic marker for inflammatory liver diseases like CHB and HC.
  • Further research is warranted to elucidate the precise mechanisms linking MIF polymorphism to liver disease pathogenesis.
Keywords:
CHBMIFPolymorphism

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...